Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620199 | 1.00 | PDCD1 (0.81) | PDCD1CD274 | |
| SCHEMBL20294094 | 0.90 | PDCD1 (1.00) | PDCD1CD274 | |
| Hydrochloric Acid SCHEMBL23363718 | 0.89 | PDCD1 (0.98) | PDCD1CD274 | |
| SCHEMBL23633083 | 0.89 | PDCD1 (0.72) | PDCD1CD274 | |
| SCHEMBL21564991 | 0.87 | PDCD1 (0.77) | PDCD1CD274 | |
| SCHEMBL21565783 | 0.86 | PDCD1 (0.92) | PDCD1CD274 | |
| SCHEMBL20294132 | 0.85 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL22660179 | 0.85 | PDCD1 (0.79) | PDCD1CD274 | |
| SCHEMBL20294313 | 0.85 | PDCD1 (0.74) | PDCD1CD274 | |
| SCHEMBL29447335 | 0.85 | PDCD1 (0.79) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230111910-A1 | PD-1/PD-L1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-112812113-B | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021096849-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| CN-112812113-A | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111910-A1 | PD-1/PD-L1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.